Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 2/20 | 0.40 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.39 |
| ▸ | ARG1 | P05089 | 1/20 | 0.36 |
| ▸ | ARG2 | P78540 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | FAAH | O00519 | 1/20 | 0.33 |
| ▸ | PHGDH | O43175 | 1/20 | 0.33 |
| ▸ | MGLL | Q99685 | 1/20 | 0.33 |
| ▸ | PNMT | P11086 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.32 |
| ▸ | PAOX | Q6QHF9 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12936745 | 0.98 | HRH3 (0.42) | KDM1AHRH3ARG1ARG2GAA | |
| SCHEMBL12936758 | 0.98 | HRH3 (0.42) | KDM1AHRH3ARG1ARG2GAA | |
| SCHEMBL5857741 | 0.98 | HRH3 (0.42) | KDM1AHRH3ARG1ARG2GAA | |
| SCHEMBL12936756 | 0.98 | HRH3 (0.42) | KDM1AHRH3ARG1ARG2GAA | |
| SCHEMBL5857565 | 0.98 | HRH3 (0.42) | KDM1AHRH3ARG1ARG2GAA | |
| SCHEMBL12936760 | 0.98 | HRH3 (0.42) | KDM1AHRH3ARG1ARG2GAA | |
| SCHEMBL12936751 | 0.98 | HRH3 (0.42) | KDM1AHRH3ARG1ARG2GAA | |
| SCHEMBL12936748 | 0.98 | HRH3 (0.42) | KDM1AHRH3ARG1ARG2GAA | |
| SCHEMBL12936743 | 0.98 | HRH3 (0.42) | KDM1AHRH3ARG1ARG2GAA | |
| SCHEMBL12936744 | 0.98 | HRH3 (0.42) | KDM1AHRH3ARG1ARG2GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8846294-B2 | Photoresist composition | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2014-09-30 | — | — | US | disclosed |
| US-8846294-B2 | Photoresist composition | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2014-09-30 | — | — | US | disclosed |
| CN-103429607-A | C-17 and C-3 modified triterpenoids with HIV maturation inhibitory activity | BRISTOL MYERS SQUIBB CO | 2013-12-04 | — | — | CN | disclosed |
| US-20120251946-A1 | PHOTORESIST COMPOSITION | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2012-10-04 | — | — | US | disclosed |
| US-20120251946-A1 | PHOTORESIST COMPOSITION | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2012-10-04 | — | — | US | disclosed |
| US-7112594-B2 | Fused bicyclic amide compounds and medicinal use thereof | MITSUBISHI PHARMA CORPORATION (JP) | 2006-09-26 | — | — | US | disclosed |
| US-7015218-B1 | Amide compounds and medicinal use thereof | MITSUBISHI PHARMA CORPORATION (JP) | 2006-03-21 | — | — | US | disclosed |
| EP-1176140-B1 | AMIDE COMPOUNDS AND MEDICINAL USE THEREOF | MITSUBISHI PHARMA CORP (JP) | 2004-12-29 | — | — | EP | disclosed |
| US-20030203909-A1 | Fused bicyclic amide compounds and medicinal use thereof | MITSUBISHI PHARMA CORPORATION (JP) | 2003-10-30 | — | — | US | disclosed |
| EP-1310488-A1 | FUSED BICYCLIC AMIDE COMPOUNDS AND MEDICINAL USE THEREOF | Mitsubishi Pharma Corporation (JP) | 2003-05-14 | — | — | EP | disclosed |
| EP-0783490-B1 | 1-ACYL-4-ALIPHATIC AMINOPIPERIDINE COMPOUNDS | NOVARTIS AG (CH) | 2002-02-06 | — | — | EP | disclosed |
| EP-1176140-A1 | AMIDE COMPOUNDS AND MEDICINAL USE THEREOF | Mitsubishi Pharma Corporation (JP) | 2002-01-30 | — | — | EP | disclosed |
| US-5935951-A | ANTAGONIST AGAINST SUBSTANCE P | NOVARTIS FINANCE CORPORATION (US) | 1999-08-10 | — | — | US | disclosed |
| EP-0783490-A1 | 1-ACYL-4-ALIPHATYLAMINOPIPERIDINE COMPOUNDS | Novartis AG (CH) | 1997-07-16 | — | — | EP | disclosed |
| WO-1996010562-A1 | 1-ACYL-4-ALIPHATYLAMINOPIPERIDINE COMPOUNDS | NOVARTIS AG (CH) | 1996-04-11 | — | — | WO | disclosed |
| CN-1091288-A | The oxytocin antagonist | OTSUKA PHARMA CO LTD (JP) | 1994-08-31 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030203909-A1 | Fused bicyclic amide compounds and medicinal use thereof | BET1, NFATC1, ARG1 | KDM1A 179/4885HRH3 38/4885ARG1 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.